# FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

Study · id `cardio:ct-nct01524705` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01524705](<https://clinicaltrials.gov/study/NCT01524705>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01524705

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.

## Technical summary

Registry record NCT01524705. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-07 (actual). Results posted on 2023-12-29.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 102 participants (enrolled count; ClinicalTrials.gov record NCT01524705, source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01524705, source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)
- Primary completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01524705, source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)
- Completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01524705, source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)
- Results first posted: 2023-12-29 (ClinicalTrials.gov record NCT01524705, source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01524705, source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01524705-2023-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
- Acronym: FLAT-SUGAR
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin Glargine
- Intervention (Drug): Metformin
- Intervention (Drug): Prandial insulin
- Intervention (Drug): Exenatide
- Lead sponsor: University of Washington
- Lead sponsor class: OTHER
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY
- Collaborator: Astra Zeneca, Bristol-Myers Squibb
- Collaborator class: OTHER
- Collaborator: DexCom, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Becton, Dickinson and Company
- Collaborator class: INDUSTRY
- Collaborator: Medicomp
- Collaborator class: UNKNOWN
- Collaborator: University of Texas
- Collaborator class: OTHER
- Collaborator: US Department of Veterans Affairs
- Collaborator class: FED
- Collaborator: Biomedical Research Institute of New Mexico
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Washington (`cardio:org-university-of-washington`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Astra Zeneca, Bristol-Myers Squibb (`cardio:org-astra-zeneca-bristol-myers-squibb`)
- Registry lists this organization as a collaborator: DexCom, Inc. (`cardio:org-dexcom-inc`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: University of Texas (`cardio:org-university-of-texas`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk (`cardio:pubmed-27208320`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes (`cardio:pubmed-26068865`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: dc7c38b8f7231bff60bf4f545d8c2dbe5ee91e08b16165799a7b7dc366e4a48b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
